Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms: Effects of Prostate Size

Roehrborn, Claus G.; Kaplan, Steven A.; Jones, J. Stephen; Wang, Joseph T.; Bavendam, Tamara; Guan, Zhonghong

doi:10.1016/j.eururo.2008.06.032

Cited by 67 publications

(48 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, several groups have evaluated the efficacy and tolerability of ComRx in men with OAB and BOO. A multicenter randomized trial was conducted to investigate the implications of TER and tamsulosin (TIMES study) in men with LUTS (15), whereas others performed subgroup analyses using PSA, prostate size, and IPSS (6,19,20). Treatment success was defined as the patients' perceptions of treatment benefit and was reported as 61.7% in placebo, 65.1% in TER, 70.8% in tamsulosin, and 80% in ComRx therapies.…”

Section: Discussionmentioning

confidence: 99%

Optimizing individual treatment outcomes in men with lower urinary tract symptoms using storage subscale score/total International Prostate Symptom Score (IPSS) as a new IPSS ratio

Altintaş¹,

Acar²,

Eskiçorapçı³

et al. 2014

Turk J Med Sci

View full text Add to dashboard Cite

IntroductionLower urinary tract symptoms (LUTS) indicate the pathologies of storage, voiding, and the postmicturition phases of urination (1). The results of a large prevalence study showed that storage symptoms such as urine frequency, nocturia, urgency, and urge incontinence were more prevalent (51.3%) than other LUTS in men (2). In recent years, the paradigm shifted from the prostate to the bladder for understanding, diagnosis, and treatment strategies of LUTS in men. Accordingly, detrusor overactivity (DO) and bladder outlet obstruction (BOO) play integral roles in men with LUTS (3). Overactive bladder (OAB) symptoms have more deteriorating effects on health-related quality of life (QoL) than other LUTS (4,5). Furthermore, recent studies have emphasized that combination therapy (ComRx) with α-blockers and antimuscarinics had better results in men with BOO who had mixed symptoms (6). In contrast, LUTS in men are often still treated with therapies targeting the prostate even if they have OAB symptoms (1).

show abstract

Section: Discussionmentioning

confidence: 99%

Optimizing individual treatment outcomes in men with lower urinary tract symptoms using storage subscale score/total International Prostate Symptom Score (IPSS) as a new IPSS ratio

Altintaş¹,

Acar²,

Eskiçorapçı³

et al. 2014

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…Over the last years, studies have reported that the combined therapy of an antimuscarinic agent plus an α-blocker appears to be an effective and relatively safe treatment option with promising results in patients with BOO and OAB [12,15]. To the best of our knowledge, there are a limited number of studies that investigated the safety and the efficacy of fesoterodine combined with an α-blocker for the treatment of patients with LUTS due BPH and OAB [16].…”

Section: Discussionmentioning

confidence: 99%

“…However, many patients may continue to experience bothersome storage symptoms and it is extremely difficult or even impossible to make a direct link between symptoms and BPH in clinical practice. It is currently believed that LUTS in men may arise from bladder dysfunction causing OAB symptoms independently of prostate enlargement and BOO [12,13]. …”

Section: Discussionmentioning

confidence: 99%

Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: Combined Treatment with Fesoterodine Fumarate Extended-Release and Tamsulosin - A Prospective Study

Konstantinidis

Samarinas²,

Andreadakis

et al. 2012

Urol Int

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of fesoterodine extended-release (ER) plus tamsulosin in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Patients and Methods: Men aged ≥50 years, with LUTS, prostate volume ≤60 ml and International Prostate Symptom Score (IPSS) ≥13 were enrolled in this study. 173 consecutive patients were treated initially with tamsulosin (0.4 mg) for 1 week. At the second visit, 47 patients out of the sample of 173 who were still experiencing inconvenient LUTS were randomized into two groups. The first group received a therapy with tamsulosin and fesoterodine combination (group 1, n = 24) while the second continued the therapy with the single administration of tamsulosin (group 2, n = 23) for an additional 4-week period. Results: There was no statistically significant differencein age, prostate volume, Q_max, and postvoid residual urine between the two groups. A statistical significance appeared in the combination group regarding the storage and the total IPSS values among the second and third visits (10.5 ± 1.4 to 8.5 ± 1.3 and 16.1 ± 1.8 to 13.7 ± 1.5 respectively). Conclusion: Regarding bothersome LUTS and storage symptoms, fesoterodine ER and tamsulosin combination was significantly more effective than the single administration of tamsulosin.

show abstract

“…Men with small prostates and moderate-to-severe LUTS, including OAB symptoms, seem to benefit from Tolterodine ER monotherapy, while Tolterodine ER plus Tamsulosin combination appears to be effective regardless of prostate size. 21,22 In patients with mixed urinary incontinence with predominant urge incontinence, Khullar et al observed that those treated with Tolterodine ER experienced less urinary frequency, urgency episodes and UUI episodes (−12.3 versus −8.0) and increased median volume voided per micturition compared to placebo. 23 In OAB patients without incontinence, Tolterodine ER is well-tolerated and reduces both diary and nocturnal severe OAB micturitions (−3.2 and −1.1 episodes respectively) as well as mean urgency ratings and frequency-urgency sum (treatment difference vs. placebo: −19.5; P = 0.003).…”

Section: Efficacy Of Tolterodine Ermentioning

confidence: 99%

Clinical Use of Tolterodine Extended Release in Overactive Bladder

Adli

Corcos

2012

Clin Med�Insights�Urol

View full text Add to dashboard Cite

Abstract:Overactive bladder (OAB) is a common problem whose prevalence increases with advancing age and compromises health-relatedqualityoflife.TolterodinewasthefirstantimuscarinicdrugspecificallydesignedtotreatOAB. ThroughMEDLINE,wereviewedarticles,standardizationreportsandmeetingabstracts,publishedbetween2001and2011,ontheefficacy and tolerability of Tolterodine extended release (ER). Our search terms included Tolterodine, extended release, overactive bladder, therapeuticuse,efficacy,tolerance,andadverseevents. TolterodineER,viasteadydrugreleaseduringthedaytime,givesthebenefitofconstantserumconcentrationandthusbetterefficacy and tolerability in comparison to Tolterodine immediate release, even in elderly patients with co-morbid conditions.

show abstract

Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms: Effects of Prostate Size

Cited by 67 publications

References 26 publications

Optimizing individual treatment outcomes in men with lower urinary tract symptoms using storage subscale score/total International Prostate Symptom Score (IPSS) as a new IPSS ratio

Optimizing individual treatment outcomes in men with lower urinary tract symptoms using storage subscale score/total International Prostate Symptom Score (IPSS) as a new IPSS ratio

Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: Combined Treatment with Fesoterodine Fumarate Extended-Release and Tamsulosin - A Prospective Study

Clinical Use of Tolterodine Extended Release in Overactive Bladder

Contact Info

Product

Resources

About